Market Research Report - 242924
Systemic Nasal Sprays: Products, Players, Markets and Forecasts
|Published by||Greystone Research Associates|
|Systemic Nasal Sprays: Products, Players, Markets and Forecasts|
|Published: June 1, 2012||Content info:||
This publication has been discontinued on September 5, 2012.
Greystone Research Associates is pleased to announce the publication of a new market study. Systemic Nasal Sprays: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug developers, device packaging designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for systemic drugs that are administered intranasally. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Drug developers and researchers are discovering that the accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics, systemically as well as across the blood-brain barrier to the CNS.
Nasal delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patientfriendly and cost-effective. Intranasal administration is well positioned to take advantage of these trends and evolve into a significant role in the future of pharmaceutical development and commercialization. Intranasal delivery will grow at the expense of the predominant drug delivery methods (oral and parenteral), which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.
Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.